OBI-888 completes Phase I safety evaluation and demonstrates its safety and tolerability with no major concerns

Date of occurrence of the event: Jun 15, 2019 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A Cause of occurrence: OBI-888 completed safety evaluation in a phase I dose escalation phase. Trial results demonstrated OBI-888’s safety and tolerability with no major safety […]

This article is password protected.

To view the content, please enter your password in the field below